Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by palinc2000on Jun 25, 2021 10:09am
111 Views
Post# 33449953

RE:Manager or Global Manager, Pricing and Reimbursement

RE:Manager or Global Manager, Pricing and ReimbursementI would like  to see the proforma  organization chart ,,,,,,vs the one that existed just over a year ago when Paul became the CEO...In the lrecent CC S Paul always mentioned that the TH of today is not the TH of a year ago,,,,I think we have not felt this dramatic change as much as he did since our attention is mainly focused on the PR s and the SP.....A lot of work and organization building is being done behind the scene but there is a new Thera being built .
I think Paul should share his vision more openly and elaborate on his vision and mission


scarlet1967 wrote:
This recent job posting is interesting as the applicant will be responsible for developing plans related to reimbursement of current and future drugs in HIV, Oncology and NASH.
 
“Reporting to the Global Commercial Officer, the Global Pricing & Reimbursement Lead will play a critical leadership role in developing, leading and coordinating plans and related core deliverables aimed at building, shaping and expanding access and securing reimbursement for Theratechnologies current and future products in HIV, oncology, and hepatology (NASH). 
Key Responsibilities
Provide immediate support and strategic direction to optimize pricing and expand the reimbursement of products in Europe and other international.
Increase corporate visibility and build alliances with key stakeholders to support the successful reimbursement of Oncology and NASH launch assets in priority countries.
Identify and partner with strategic partners (outside consultants) to achieve optimal outcomes for reimbursement and pricing strategies and local implementation….”
https://www.linkedin.com/jobs/view/2609260708
 


<< Previous
Bullboard Posts
Next >>